Introduction {#sec1}
============

Diabetes is a worldwide public health problem that has prevalence greater than 5.71% in adults \[[@B1]\]. Chronic hyperglycemia leads to a high risk of cardiovascular events \[[@B2]\]. Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Diabetic cardiomyopathy (DCM) is defined as cardiac hypertrophy that is independent of hypertension and coronary artery disease (CAD). The three main risk factors of DCM are insulin resistance, hyperinsulinemia, and hyperglycemia. To date, some cellular and molecular defects, including impaired insulin signaling, hyperglycemia, glucotoxicity, cardiac lipotoxity, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum (ER) stress, and cardiomyocyte apoptosis, have been reported as primary causes of DCM pathogenesis \[[@B3],[@B4]\]. Treatments providing glycemic control and cardiovascular protection are important to improve the health of people all over the world \[[@B5]\].

Glucagon-like peptide-1 (GLP-1) is secreted from L-cells in the gut. In addition, to controlling blood glucose levels, GLP-1 also reduces gastric emptying and inhibits appetite. However, GLP-1 can be digested quickly by dipeptidyl peptidase-4 (DPP-4). In clinical practice, the GLP-1 receptor (GLP-1R) agonist liraglutide was effective at controlling blood glucose levels. In addition to pancreatic α and β cells, GLP-1Rs are also found in the heart. More and more clinical trials and animal experiments have shown evidence of the protective cardiac effects of liraglutide, independent of its effects on blood glucose levels. Short-term liraglutide treatment mildly improves left ventricular ejection fraction (LVEF) in ST-segment elevation myocardial infarction patients \[[@B6]\]. In type 1 diabetic rats, liraglutide inhibits cardiac steatosis, oxidative stress, and apoptosis through activating the activated protein kinase (AMPK)-sirtuin 1 (Sirt1) pathway \[[@B7]\]. However, the exact mechanism of the beneficial effects of liraglutide on cardiac tissue in diabetic rats remains to be elucidated.

Therefore, the present study aimed to investigate whether liraglutide has protective cardiac effects and its underlying mechanism in type 2 diabetic rats. We employed a global microarray analysis combined with bioinformatics to explore key genes and pathways affected by liraglutide in cardiac tissue from diabetic rats.

Materials and methods {#sec2}
=====================

Animal treatments and diets {#sec2-1}
---------------------------

Five-week-old male Sprague--Dawley (SD) rats, provided by the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China, SCXK-2014-0013), were maintained in a pathogen-free environment with a 12-h light/dark cycle and free access to food and water. Animal experiments followed the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication number 85-23, revised 1996) and were approved by the Animal Care Committee of the Peking Union Medical Hospital Animal Ethics Committee (Project XHDW-2015-0051, 15 February 2015). After acclimatization, the rats were randomly divided into four groups (*n*=6 for each group): control, diabetic, low-dose liraglutide (Llirag), and high-dose liraglutide (Hlirag) groups. The control group was fed a standard rodent diet (kcal%: 10% fat, 20% protein, and 70% carbohydrate; 3.85 kcal/g); the other three groups were fed a high-fat diet (HFD) (kcal%: 45% fat, 20% protein, and 35% carbohydrate; 4.73 kcal/g, Research Diet, New Brunswick, NJ, U.S.A.). After 4 weeks of HFD feeding, diabetes was induced in the rats by streptozotocin (STZ, 30 mg/kg) injection. Fasting blood glucose levels higher than 11.1 mmol/l were considered standard for the diabetic model. Then, 0.2 or 0.4 mg/kg/day liraglutide (i.h.) was administered to the Llirag and Hlirag groups, respectively. Control and diabetic groups were injected with the same volume of normal saline. Body weights and fasting blood glucose levels (Bayer Contour TS glucometer, Hamburg, Germany) were recorded monthly. After 12 weeks of treatment, an oral glucose tolerance test, in which 20% glucose was gavaged at a dose of 2 g/kg, was performed after 10 h of fasting. Tail vein blood glucose levels at 0, 30, 60, and 120 min were measured. At the end of the study, all rats were fasted for 10 h and anesthetized with ketamine (100 mg/kg i.p., Pharmacia and Upjohn Ltd, Crawley, U.K.), then blood samples were collected from the abdominal aorta. Finally, the rats were killed by decapitation. Cardiac tissue was quickly collected, frozen in liquid nitrogen, and stored at −80°C for gene microarray analysis.

Metabolic profile analysis {#sec2-2}
--------------------------

Triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels were measured by an enzyme end point method (Roche Diagnostics, GmbH, Mannheim, Germany). Fasting serum adiponectin and insulin levels were determined by enzyme-linked immunosorbent assay (Millipore, Billerica, MA, U.S.A.). Homeostasis model assessment of insulin resistance (HOMA-IR) scores was calculated using the following formula: FBG (mmol/l) × fasting insulin (μIU/ml)/22.5.

Serum nitric oxide and antioxidant markers {#sec2-3}
------------------------------------------

Serum nitric oxide (NO) and GSH/GSSG levels were determined using Fluorometric Assay Kit (Cayman Chemical, Ann Arbor, MI, U.S.A.) and Thiol Green Indicator fluorometric method (Abcam, Cambridge, MA, U.S.A.), respectively.

Tail cuff systolic blood pressure and heart rate measurements {#sec2-4}
-------------------------------------------------------------

Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff plethysmography (BP98A, Softron, Tokyo, Japan). After prewarming at 25°C for at least 5 min, the first five cycles were used as acclimatization cycles. After that, the mean blood pressure was recorded for the next five consecutive cycles.

Left ventricle function measurement by echocardiography {#sec2-5}
-------------------------------------------------------

Rats were anesthetized by inhaling 1% isoflurane with 99% O~2~. During anesthesia, left ventricle (LV) diameter was determined using a Vevo 2100 Ultrasound System (Visual Sonics, Toronto, Ontario, Canada). Fractional shortening (FS) was calculated as follow: FS% = (LVEDD -- LVESD)/LVEDD × 100, where LVEDD and LVESD are the LV end-diastolic diameter and the LV end-systolic diameter, respectively \[[@B8]\]. Increased FS indicated better LV contractile function \[[@B9]\].

RNA extraction and gene microarray hybridization {#sec2-6}
------------------------------------------------

Total RNA was extracted from cardiac tissue by using a mirVana™ RNA Isolation Kit (Ambion, Sao Paulo, SP, Brazil). Total RNA was transcribed into double-stranded cDNA and then synthesized into double-stranded cRNA. The second cycle cRNA was then labeled with biotin. The biotinylated cRNA was purified, fragmented, and hybridized to an Affymetrix GeneChip Rat Gene 2.0 ST whole transcript-based array (Affymetrix Technologies, Santa Clara, CA, U.S.A.). After washing and staining, the microarrays were scanned using an Affymetrix Scanner 3000 7G (Santa Clara, CA, U.S.A.).

Microarray bioinformatics analysis {#sec2-7}
----------------------------------

Expression Console Software (version 1.4.1, Affymetrix, Santa Clara, CA, U.S.A.) was used to analyze the microarray signals. Differentially expressed genes were defined as having a fold change \>1.5 and *P*-value \<0.05 (one-way ANOVA). The raw microarray data have been submitted to the Gene Expression Omnibus (GEO) repository (GSE102194). The enrichment analysis of differentially expressed genes was performed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis with Database for Annotation, Visualization, and Integrated Discovery (DAVID) software (<http://david.abcc.ncifcrf.gov/>) \[[@B10]\]. The gene interaction network was drawn using String software (<http://string-db.org/>) \[[@B11]\].

Real-time PCR {#sec2-8}
-------------

Total RNA was extracted from cardiac tissue. Reverse transcription products were tested by real-time PCR. The primers are listed in [Table 1](#T1){ref-type="table"}. Real-time PCR was performed on an ABI Prism 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, U.S.A.). The cycling conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 30 s. β-actin was used as an internal control. Samples were run in triplicate. The 2^−ΔΔ*C*^~t~ method was used to calculate the relative expression levels. Table 1Oligonucleotide sequences for qPCR analysisGene symbolGenbank IDForward primerReverse primerProduct size (bp)*Angptl3*NM_001025065AAAGGGTTTTGGGAGGCTTGACCCAAAAGCGCTATGGTCTC117*Dgat1*NM_053437GAACCGCTTCTTCCAAGGGAAGAACTCCAGGCCCAGGTTA177*Dgat2*NM_001012345ACCTACCTCGGATCTCGACCCTGATCCATGCCCCAGCC105*Ephx2*NM_022936CGTTCGACCTTGACGGAGTGCTGGAAAGCGCCAAGTAGGA107*Nr1h3*NM_031627GAGTCATCCGAGCCTACAGCAAGAATCCCTTGCAGCCCTC191*Pparα*NM_013196ATTGGCGTTCGCAGCTGTTTCTCGTGTGCCCTCCCTCAAG102*Srebf1*NM_001276707CCATGGACGAGCTACCCTTCGGCATCAAATAGGCCAGGGA149*β-actin*NM_031144ACTCTGTGTGGATTGGTGGCCGCAGCTCAGTAACAGTCCG140[^1]

Statistical analysis {#sec2-9}
--------------------

GraphPad Prism software (version 5.0, San Diego, CA, U.S.A.) was used for statistical analyses. All values are shown as the mean ± S.D. Group data were analyzed using one-way ANOVA followed by Student's *t* test. *P*\<0.05 was considered to be statistically significant.

Results {#sec3}
=======

Effect of liraglutide on body weight, serum lipid profile, blood glucose, adiponectin, and serum fasting insulin levels {#sec3-1}
-----------------------------------------------------------------------------------------------------------------------

Liraglutide significantly reduced the body weights of diabetic rats (*P*\<0.05, [Figure 1](#F1){ref-type="fig"}A). In addition, liraglutide dose dependently reduced fasting blood glucose levels and blood glucose and area under the curve (AUC) values for oral glucose tolerance tests ( OGTTs, *P*\<0.01, [Figure 1](#F1){ref-type="fig"}B--D). The rats that underwent 12-week liraglutide treatment had lower TC (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}E) and LDL-c levels (*P*\<0.05, [Figure 1](#F1){ref-type="fig"}H). Only the high dose of liraglutide reduced serum TG levels and increased serum adiponectin level in diabetic rats (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}F,I). Compared with diabetic rats, liraglutide-treated rats had lower serum fasting insulin levels and HOMA-IR scores (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}J,K).

![Effect of liraglutide on metabolic indexes in diabetic rats.\
(**A**) Body weight, (**B**) fasting blood glucose, (**C**) blood glucose in OGTT, (**D**) AUC in OGTT, (**E**) TC, (**F**) TG, (**G**) HDL, (**H**) LDL, (**I**) adiponectin, (**J**) fasting insulin, (**K**) HOMA-IR, (**L**) NO, (**M**) GSH, (**N**) GSSG, and (**O**) GSH/GSSG. Values are mean ± S.D. (*n*=6), \**P*\<0.05, \*\**P*\<0.01 compared with normal group; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01 compared with diabetic group; ^\$\$^*P*\<0.01 compared with Llirag group.](bsr-38-bsr20180059-g1){#F1}

Effect of liraglutide on serum NO and antioxidant markers {#sec3-2}
---------------------------------------------------------

Serum NO, GSH level, and GSH/GSSG ratio in diabetic rats were lower than control rats (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}L,M,O). Liraglutide treatment moderated this decrease (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}L,M,O). Serum GSSG level in diabetic group was higher than control rats (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}N). Liraglutide reduced serum GSSG level dose independently (*P*\<0.01, [Figure 1](#F1){ref-type="fig"}N).

Effect of liraglutide on cardiac function {#sec3-3}
-----------------------------------------

SBP, HR, LVEDD, and LVESD levels in the diabetic group were significantly increased (*P*\<0.01, [Figure 2](#F2){ref-type="fig"}A--D). However, diabetic rats had lower %FS values than normal control rats (*P*\<0.01, [Figure 2](#F2){ref-type="fig"}E). Liraglutide treatment decreased SBP, HR, LVEDD, and LVESD levels and increased % FS values (*P*\<0.01, [Figure 2](#F2){ref-type="fig"}A--E). These results suggest that liraglutide moderated LV dysfunction and decreased blood pressure and HRs.

![Effect of liraglutide on cardiac function in diabetic rats.\
(**A**) SBP, (**B**) HR, (**C**) LVEDD, (**D**) LVESD, and (**E**) FS. *n*=6. \*\**P*\<0.01 compared with control; ^\#\#^*P*\<0.01 compared with diabetic.](bsr-38-bsr20180059-g2){#F2}

Microarray data analysis of Hlirag and diabetic groups {#sec3-4}
------------------------------------------------------

A total of 269 differentially expressed genes were screened out from Hlirag group (fold change \>1.5, *P*\<0.05); these included 166 up-regulated genes and 105 down-regulated genes. The differentially expressed genes were enriched in 11 pathways (*P*\<0.001, [Table 2](#T2){ref-type="table"}). The top five pathways were cardiac muscle contraction, non-alcoholic fatty liver disease (NAFLD), oxidative phosphorylation, metabolic pathways, metabolic pathways, and Alzheimer's disease. The significant biological processes (BPs) in the GO categories are listed in [Table 3](#T3){ref-type="table"} (*P*\<0.01). The top ten BP terms were hydrogen ion transmembrane transport, cholesterol homeostasis, lipid homeostasis, positive regulation of TG biosynthetic process, fatty acid β-oxidation using acyl-CoA dehydrogenase, fatty acid β-oxidation, response to cAMP, very long-chain fatty acid catabolic process, circadian rhythm, and lipid metabolic process.

###### The enriched KEGG pathway with differentially expressed genes (*P*\<0.001)

  Pathway ID   Pathway name                                  Count   Fold enrichment   *P*-value
  ------------ --------------------------------------------- ------- ----------------- ---------------
  rno04932     NAFLD                                         14      6.003             4.39 × 10^−7^
  rno04260     Cardiac muscle contraction                    10      8.905             1.42 × 10^−6^
  rno01100     Metabolic pathways                            39      2.095             4.16 × 10^−6^
  rno00190     Oxidative phosphorylation                     12      5.7889            5.79 × 10^−6^
  rno05012     Parkinson's disease                           12      5.484             9.74 × 10^−6^
  rno05010     Alzheimer's disease                           13      4.961             9.80 × 10^−6^
  rno00640     Propanoate metabolism                         6       14.885            4.09 × 10^−5^
  rno01200     Carbon metabolism                             10      5.740             5.27 × 10^−5^
  rno00280     Valine, leucine, and isoleucine degradation   7       8.840             1.21 × 10^−4^
  rno05016     Huntington's disease                          12      4.106             1.41× 10^−4^
  rno01130     Biosynthesis of antibiotics                   12      3.806             2.73 × 10^−4^

###### The enriched GO terms with differentially expressed genes (*P*\<0.01)

  Term ID      Term name                                                                                                       Count   *P*-value        Fold enrichment   Catalog
  ------------ --------------------------------------------------------------------------------------------------------------- ------- ---------------- ----------------- ---------------------
  GO:1902600   Hydrogen ion transmembrane transport                                                                            8       1.221 × 10^−5^   0.0193            BP
  GO:0042632   Cholesterol homeostasis                                                                                         7       0.000124         0.197             BP
  GO:0055088   Lipid homeostasis                                                                                               6       0.000148         0.236             BP
  GO:0010867   Positive regulation of triglyceride biosynthetic process                                                        4       0.00105          1.669             BP
  GO:0033539   Fatty acid β-oxidation using acyl-CoA dehydrogenase                                                             4       0.00148          2.329             BP
  GO:0006635   Fatty acid β-oxidation                                                                                          5       0.00231          3.616             BP
  GO:0051591   Response to cAMP                                                                                                6       0.00245          3.825             BP
  GO:0042760   Very long-chain fatty acid catabolic process                                                                    3       0.00296          4.601             BP
  GO:0007623   Circadian rhythm                                                                                                7       0.00361          5.589             BP
  GO:0006629   Lipid metabolic process                                                                                         6       0.00458          7.039             BP
  GO:0090181   Regulation of cholesterol metabolic process                                                                     3       0.00499          7.647             BP
  GO:0043401   Steroid hormone mediated signaling pathway                                                                      5       0.00538          8.209             BP
  GO:0006631   Fatty acid metabolic process                                                                                    5       0.00606          9.213             BP
  GO:0019217   Regulation of fatty acid metabolic process                                                                      3       0.00619          9.399             BP
  GO:2000188   Regulation of cholesterol homeostasis                                                                           3       0.00619          9.399             BP
  GO:0030522   Intracellular receptor signaling pathway                                                                        4       0.00737          11.085            BP
  GO:0019432   Triglyceride biosynthetic process                                                                               3       0.00894          13.296            BP
  GO:0006366   Transcription from RNA polymerase II promoter                                                                   12      0.00976          14.419            BP
  GO:0005739   Mitochondrion                                                                                                   43      1.503 × 10^−6^   2.199             Cellular components
  GO:0005743   Mitochondrial inner membrane                                                                                    13      0.000465         3.403             Cellular components
  GO:0005777   Peroxisome                                                                                                      8       0.000731         5.373             Cellular components
  GO:0005746   Mitochondrial respiratory chain                                                                                 3       0.00620          24.584            Cellular components
  GO:0004129   Cytochrome *c* oxidase activity                                                                                 6       4.237 × 10^−5^   15.081            Molecular function
  GO:0003700   Transcription factor activity, sequence-specific DNA binding                                                    22      0.000415         2.359             Molecular function
  GO:0001077   Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   11      0.00127          3.483             Molecular function
  GO:0000978   RNA polymerase II core promoter proximal region sequence-specific DNA binding                                   12      0.00397          2.789             Molecular function
  GO:0043565   Sequence-specific DNA binding                                                                                   16      0.00479          2.265             Molecular function
  GO:0009055   Electron carrier activity                                                                                       5       0.00505          7.181             Molecular function
  GO:0003707   Steroid hormone receptor activity                                                                               5       0.00505          7.181             Molecular function
  GO:0004879   RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding                 4       0.00912          9.192             Molecular function
  GO:0046982   Protein heterodimerization activity                                                                             15      0.00946          2.170             Molecular function
  GO:0044212   Transcription regulatory region DNA binding                                                                     9       0.00950          3.054             Molecular function

All the 271 differentially expressed genes were mapped using String online software. The results showed that there were 253 interactions with a total of 256 joint edges ([Figure 3](#F3){ref-type="fig"}). Twenty-one nodes had more than ten joint edges. These nodes involved 137 joint edges. These 21 genes are listed in [Table 4](#T4){ref-type="table"}. The top ten genes were citrate synthase (*Cs*), ubiquinol-cytochrome *c* reductase core protein I (*Uqcrc1*), acyl-CoA dehydrogenase, very long chain (*Acadv1*), 3-oxoacid CoA transferase 1 (*Oxct1*), NADH dehydrogenase (ubiquinone) flavoprotein 1 (*Ndufv1*), succinate-CoA ligase, alpha subunit (*Suclg1*), enoyl CoA hydratase, short chain, 1, mitochondrial (*Echs1*), acyl-CoA dehydrogenase, C2--C3 short chain (*Acads*), and branched chain ketoacid dehydrogenase E1, α-polypeptide (*Bckdha*).

![Protein--protein interaction network in Hlirag group compared with diabetic group\
The nods stand for differentially expressed genes in Hlirag group compared with diabetic group. The lines stand for the interactions between two proteins.](bsr-38-bsr20180059-g3){#F3}

###### A list of genes with connective degree more than ten in the String network

  Gene accession       Gene symbol   Gene name                                                                  Degree
  -------------------- ------------- -------------------------------------------------------------------------- --------
  NM_130755            *Cs*          Citrate synthase                                                           20
  NM_001004250         *Uqcrc1*      Ubiquinol-cytochrome *c* reductase core protein I                          18
  NM_012891            *Acadvl*      Acyl-CoA dehydrogenase, very long chain                                    17
  NM_001127580         *Oxct1*       3-Oxoacid CoA transferase 1                                                16
  NM_001006972         *Ndufv1*      NADH dehydrogenase (ubiquinone) flavoprotein 1                             15
  NM_053752            *Suclg1*      Succinate-CoA ligase, alpha subunit                                        15
  NM_078623            *Echs1*       Enoyl CoA hydratase, short chain, 1, mitochondrial                         14
  NM_022512            *Acads*       Acyl-CoA dehydrogenase, C-2 to C-3 short chain                             13
  NM_012782            *Bckdha*      Branched chain ketoacid dehydrogenase E1, α-polypeptide                    13
  NM_134364            *Atp5b*       ATP synthase, H^+^ transporting, mitochondrial F1 complex, β-polypeptide   12
  NM_017202            *Cox4i1*      Cytochrome *c* oxidase subunit IV isoform 1                                12
  NM_145783            *Cox5a*       Cytochrome *c* oxidase, subunit Va                                         12
  NM_001107793         *Acss2*       Acyl-CoA synthetase short-chain family member 2                            11
  NM_138883            *Atp5o*       ATP synthase, H^+^ transporting, mitochondrial F1 complex, O subunit       11
  ENSRNOT00000077826   *Decr2*       2,4-Dienoyl CoA reductase 2, peroxisomal                                   11
  NM_001044242         *Pdhx*        Pyruvate dehydrogenase complex, component X                                11
  NM_001108387         *Sucla2*      Succinate-CoA ligase, ADP-forming, β-subunit                               11
  NM_001025134         *Uqcrq*       Ubiquinol-cytochrome *c* reductase, complex III subunit VII                11
  NM_019267            *Bckdhb*      Branched chain keto acid dehydrogenase E1, β-polypeptide                   10
  NM_012814            *Cox6a1*      Cytochrome *c* oxidase, subunit VIa, polypeptide 1                         10
  NM_053493            *Hacl1*       2-Hydroxyacyl-CoA lyase 1                                                  10

Confirmation by quantitative Polymerase Chain Reaction (qPCR) {#sec3-5}
-------------------------------------------------------------

To validate the microarray results, we analyzed the mRNA expression levels of representative gene by using qPCR. As shown in [Figure 4](#F4){ref-type="fig"}, the relative mRNA levels of LXRα, nuclear receptor subfamily 1, group H, member 3 (*Nr1h3*), sterol regulatory element binding transcription factor 1 (*Srebf1*) and peroxisome proliferator activated receptor α (*PPARα*) in the Hlirag group were significantly higher, whereas the mRNA levels of angiopoietin-like 3 (*Angptl3*), diacylglycerol O-acyltransferase 1 (*Dgat1*), diacylglycerol O-acyltransferase 2 (*Dgat2*), and epoxide hydrolase 2 (*Ephx2*) were lower than those in diabetic rat group (*P*\<0.01). These outcomes were consistent with the microarray results.

![Confirmation of five representative differentially expressed genes by qPCR\
Values are mean ± S.D. (*n*=6), \*\**P*\<0.01 compared with normal group; ^\#\#^*P*\<0.01 compared with diabetic group.](bsr-38-bsr20180059-g4){#F4}

Discussion {#sec4}
==========

In the present study, as expected, liraglutide reduced blood glucose levels and moderated insulin resistance in diabetic rats. Moreover, we found that liraglutide reduced the body weights in diabetic rats. Liraglutide-treated rats also had lower TC and LDL-c levels and higher adiponectin levels. Clinical trials proved that liraglutide was effective at reducing blood glucose levels and body weights \[[@B12]\]. Liraglutide at 3.0 mg/day has been approved by the U.S. Food and Drug Administration (FDA) for treating obesity since 2014. In human studies, liraglutide treatment at 3.0 mg for 56 weeks decreased insulin resistance \[[@B15]\]. In addition, liraglutide treatment dose dependently increased plasma adiponectin in Chinese type 2 diabetes \[[@B16]\].

Regarding cardiac function, we found that liraglutide reduced SBP, HR, LVEDD, and LVESD levels, increased %FS values and serum NO levels in diabetic rats. These results indicate the beneficial effects of liraglutide on cardiac function. HFD-fed mice have cardiac ceramide accumulation. One week of liraglutide treatment improved cardiac ER homeostasis and cardiac function \[[@B17]\]. A clinical trial revealed that liraglutide reduced LVEF in patients with heart failure (HF) \[[@B18]\]. Interestingly, liraglutide reduced both systolic and diastolic blood pressure in hypertensive mice through the atrial natriuretic peptide (ANP) axis \[[@B19]\]. In a meta-analysis of 16 randomized controlled trials, GLP-1 receptor agonists (exenatide and liraglutide) reduced systolic pressure (SBP) and diastole pressure (DBP) by 1--5 mmHg compared with other antidiabetic drugs in diabetic patients \[[@B20]\]. Reductions in blood pressure were not related to weight loss or hemoglobin A1c (HbA1c) improvement \[[@B21]\].

We found that liraglutide increased PPARα expression in the cardiac tissue of diabetic rats. PPARs have three forms: α, γ, and δ. They can bind with retinoid X receptor (RXR) to regulate energy utilization and storage \[[@B22]\]. Recent results implicate PPARs in the regulation of inflammation and atherosclerosis \[[@B23]\]. In the heart, both PPARα and PPARδ can regulate lipid metabolism. In addition to lipid metabolism, PPAR-γ also modulates glucose metabolism \[[@B24]\]. Previous studies found that PPAR-α expression is down-regulated in diabetic rat hearts \[[@B27]\]. Many studies indicate that oxidative stress increases in diabetic status \[[@B31],[@B32]\] and contributes to inhibition of PPAR-α in cardiomyocytes \[[@B33]\]. Our data also showed that diabetic rats had lower GSH/GSSG ratio, and liraglutide treatment increased serum GSH/GSSG ratio. GSH/GSSG ratio is an important antioxidant biomarker \[[@B34]\].

Interestingly, in our study, liraglutide reduced *Dgat1* and *Dgat2* expression in the hearts of diabetic rats. DGAT has two isoforms: DGAT1 and DGAT2. They are the enzymes that catalyze the final step in the biosynthesis of TG \[[@B35]\]. DGAT is the target gene of PPARα. DGAT2 appears to be a key enzyme that controls TG homeostasis *in vivo* and regulates fatty acid storage \[[@B36]\]. A previous study found that DGAT1 and DGAT2 expression was increased in diabetic rat hearts \[[@B37]\]. Increased DGAT expression generated reactive oxidative stress, and caused myocardial damage in DM cardiomyopathy \[[@B38]\]. Thus, our results indicate that liraglutide reverses oxidative stress generated by diabetic status to increase PPARα expression, leads to reduce the expression of DGAT, and also finally inhibits reactive oxidative stress.

Our research found that liraglutide increased *Nr1h3* (LXRα) and *Srebf1* expression in diabetic rat hearts. LXRs have important role in the regulation of cholesterol and fatty acid metabolism. It forms heterodimer with RXR \[[@B39]\]. *Srebf* is directly induced by LXRs through an RXR/LXR-binding site on the *Srebf* gene promoter \[[@B40],[@B41]\]. SREBF is a transcription factor that regulates lipogenic enzymes by binding to sterol response elements \[[@B42]\]. Thus, our data supports that liraglutide treatment activates cardiac LXRα and *Srebf1* expression in diabetic rats.

We also found that liraglutide reduced *Ephx2* expression in diabetic rat hearts. Soluble epoxide hydrolase (sEH) is an *Ephx2* gene product. Arachidonic acid (AA) can be transferred to epoxyeicosatrienoic acids (EETs) by cytochrome P-450 (CYP) epoxygenases. EETs are signaling molecules that regulate blood pressure \[[@B43]\], inflammation \[[@B44],[@B45],[@B47],[@B48]\], and glucose homeostasis \[[@B49],[@B50]\]. However, EETs have a short half-life and may be metabolized by sEH into dihydroxyeicosatrienoic acids (DHETs) with relatively weak activity. Hearts in sEH null mice had improved post-ischemic recovery of Lv developed pressure (LVDP), reduced infarct size after ischemia and reperfusion \[[@B51]\], and reduced survival after cardiac arrest and cardiopulmonary resuscitation \[[@B52]\]. Therefore, sEH is a promising target for treating cardiovascular disease. sEH inhibitors have been indicated as beneficial treatments in animal models of high blood pressure \[[@B43],[@B44],[@B46]\], inflammation \[[@B44],[@B48],[@B53]\], myocardial injury \[[@B44],[@B54]\], ischemia--reperfusion \[[@B57],[@B58]\], pathological cardiac hypertrophy \[[@B44]\], and insulin resistance \[[@B49],[@B50]\] and have been shown to protect heart structure and function \[[@B59]\]. Our study provided evidence that as a sEH ingibitor, liraglutide can preserve cardiac function.

We also found that liraglutide reduced *Angptl3* expression in diabetic rat hearts. Lipoprotein lipase (LPL) metabolized TG into free fatty acids (FFAs). LPL overexpression is correlated with reduced plasma TG levels and decreased cardiovascular risks \[[@B60]\]. However, LPL null models have severe hypertriglyceridemia \[[@B60]\]. The angiopoietin-like protein (ANGPTL) family is a key regulator of LPL \[[@B61],[@B62]\]. ANGPTL3 is an endogenous inhibitor of LPL. Rare loss-of-function variants for ANGPTL3 have been associated with decreased TG levels as well as decreased low-density lipoprotein-cholesterol (LDL-c) and high-density lipoprotein-cholesterol (HDL-c) levels in family and general population studies in humans \[[@B62]\]. In addition, these subjects demonstrate an absence of coronary atherosclerotic plaques \[[@B71]\]. Another human population study showed that plasma ANGPTL3 levels were increased in myocardial infarction patients \[[@B71]\]. Heterozygous carries of ANGPTL3 loss-of-function mutations had a 34% reduction in CAD risk \[[@B71]\]. *Angptl3* deletion was also reported to reduce the development of atherosclerosis in apolipoprotein E (apoE)-deficient mice \[[@B72]\]. Recently, a human monoclonal antibody against Angptl3 in dyslipidemic mice and against ANGPTL3 in healthy human subjects with elevated levels of TGs or LDL-c significantly reduced serum TG, HDL-c, and LDL-c levels and decreased the odds of atherosclerotic cardiovascular disease \[[@B73]\]. Another research group showed that treating mice and human subjects with antisense oligonucleotides targeting Angptl3 messenger RNA reduced atherogenic lipoproteins and retarded the progression of atherosclerosis \[[@B74]\].

Conclusion {#sec5}
==========

In conclusion, liraglutide prevents cardiac dysfunction by activating cardiac PPARα to inhibit *Dgat* expression and oxidative stress in diabetic rats ([Figure 5](#F5){ref-type="fig"}). The present study provides a potential mechanism for the protective cardiac effects of a GLP-1 analog in a model of diabetes.

![Liraglutide activates PPARα, which binds to RXR\
Then PPARα inhibits its target gene, *DGAT* to inhibit oxidative stress. Liraglutide also activates *Nr1h3* and SREBP and inhibits Angptl3 to activate LPL, leading the production of FFAs. Moreover, liraglutide inhibits sEH expression to increase EET.](bsr-38-bsr20180059-g5){#F5}
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ANGPTL3

:   angiopoietin-like 3

AMPK

:   activated protein kinase

apoE

:   apolipoprotein E

AUC

:   area uncer the curve

BP

:   biological process

CAD

:   coronary artery disease

DBP

:   diastole pressure

DCM

:   diabetic cardiomyopathy

DGAT

:   diacylglycerol O-acyltransferase

EET

:   epoxyeicosatrienoic acid

ER

:   endoplasmic reticulum

FS

:   fractional shortening

GLP-1

:   glucagon-like peptide-1

GLP-1R

:   GLP-1 receptor

GO

:   gene ontology

HbA1c

:   hemoglobin A1c

HDL-c

:   high-density lipoprotein-cholesterol

HFD

:   high-fat diet

Hlirag

:   high-dose liraglutide

HOMA-IR

:   homeostasis model assessment of insulin resistance

HR

:   heart rate

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

LDL-c

:   low-density lipoprotein-cholesterol

Llirag

:   low-dose liraglutide

LV

:   left ventricular

LVEDD

:   LV end-diastolic diameter

LVEF

:   LV ejection fraction

LVESD

:   LV end-systolic diameter

OGTT

:   oral glucose tolerance test

PPAR

:   peroxisome proliferator activated receptor

qPCR

:   quantitative polymerase chain reaction

RXR

:   retinoid X receptor

SBP

:   systolic blood pressure

sEH

:   soluble epoxide hydrolase

SBP

:   systolic pressure

Sirt1

:   sirtuin 1

STZ

:   streptozotocin

TC

:   total cholesterol

TG

:   triglyceride

[^1]: Abbreviations: *Angptl3*, angiopoietin-like 3; *Dgat1*, diacylglycerol O-acyltransferase 1; *Dgat2*, diacylglycerol O-acyltransferase 2; *Ephx2*, epoxide hydrolase 2; *Nr1h3* (LXRα), nuclear receptor subfamily 1, group H, member 3; *Pparα*, peroxisome proliferator activated receptor α, *Srebf1*, sterol regulatory element binding transcription factor 1.
